Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer

被引:57
作者
D'Ugo, D.
Persiani, R.
Rausei, S.
Biondi, A.
Vigorita, V.
Boccia, S.
Ricci, R.
机构
[1] Univ Cattolica Sacro Cuore, Dept Surg, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Inst Hyg, I-00168 Rome, Italy
[3] Univ Cattolica Sacro Cuore, Div Pathol, I-00168 Rome, Italy
[4] Catholic Univ, Hi Tech Ctr Educ & Res Biomed Sci, Div Surg Oncol, I-86100 Campobasso, Italy
来源
EJSO | 2006年 / 32卷 / 10期
关键词
locally advanced gastric cancer; laparoscopic staging; neoadjuvant chemotherapy; pathologic response; tumor downstaging;
D O I
10.1016/j.ejso.2006.07.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Aim of this study is the evaluation of the effects induced by neoadjuvant chemotherapy (NACT) and its impact oil survival on a series of locally advanced gastric carcinomas. Methods: Downstaging was assessed comparing pre-treatment clinical and laparoscopic staging with post-operative pathologic staging on 30 consecutive patients who completed a 3-year follow-up. Tumor downstaging and the grade of pathologic response were included in a statistical correlation between tumor regression induced by NACT and 3-year survival. Results: In this series tumor downstaging was obtained in 13 out of 30 patients. After the completion of 3-year follow-up, overall Survival was > 37.5 months with an overall survival rate of 56.7%; this figure reached up to 70.8% in those cases who benefited from a RO-resection (24/30 patients: RO-resection rate 80.0%). Conclusions: In this study the 3-year survival for locally advanced gastric cancer treated by NACT prior to "D2" surgical resection, compares favourably with historical series treated by surgery alone. Patients who obtained T-downstaging and subsequently benefited from a RO-resection had a definitely better chance of cure, according to a complete 3-year follow-up. (c) 2006 Elsevier Ltd. Ail rights reserved.
引用
收藏
页码:1105 / 1109
页数:5
相关论文
共 35 条
[1]  
AJANI JA, 1991, CANCER-AM CANCER SOC, V68, P1501, DOI 10.1002/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO
[2]  
2-L
[3]   Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer [J].
Barone, C ;
Cassano, A ;
Pozzo, C ;
D'Ugo, D ;
Schinzari, G ;
Persiani, R ;
Basso, M ;
Brunetti, IM ;
Longo, R ;
Picciocchi, A .
ONCOLOGY, 2004, 67 (01) :48-53
[4]  
Becker K, 1999, CANCER, V85, P1484, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1484::AID-CNCR8>3.0.CO
[5]  
2-I
[6]   Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].
Becker, K ;
Mueller, JD ;
Schulmacher, C ;
Ott, K ;
Fink, U ;
Busch, R ;
Böttcher, K ;
Siewert, JR ;
Höfler, H .
CANCER, 2003, 98 (07) :1521-1530
[7]  
Bottcher K, 2000, THERAPY GASTROINTEST, P217
[8]  
Cox D.R., 1984, MONOGRAPHS STAT APPL
[9]  
Cunningham D., 2005, J CLIN ONCOL, V23, P4001, DOI DOI 10.1200/JCO.2005.23.16_SUPPL.4001
[10]   Selection of locally advanced gastric carcinoma by preoperative staging laparoscopy [J].
DUgo, DM ;
Persiani, R ;
Caracciolo, F ;
Ronconi, P ;
Coco, C ;
Picciocchi, A .
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 1997, 11 (12) :1159-1162